Background {#s1}
==========

Type 2 diabetes mellitus, characterized by abnormal glucose metabolism and an inadequate compensatory insulin secretion response, accounts for over 90% of all cases of diabetes.[@R1] Treatment of type 2 diabetes often targets abnormal glucose levels, yet outcomes measured in clinical trials of glucose-lowering interventions are inconsistent[@R2] and this heterogeneity in outcomes limits the usefulness of trial findings to patients and other decision-makers.[@R3] The [S]{.ul}electing [C]{.ul}ore [O]{.ul}utcomes for [R]{.ul}andomised [E]{.ul}ffectiveness trials [I]{.ul}n [T]{.ul}ype 2 diabetes (SCORE-IT) study[@R5] aims to address these issues by developing a core outcome set (COS) for use in clinical trials of glucose-lowering interventions in people with type 2 diabetes.

COS represent agreed standardized sets of outcomes that should be measured and reported, as a minimum, in all clinical trials for a specific health condition.[@R6] The development and implementation of COS can improve the relevance and consistency of trial outcomes and allow the results of clinical research to be pooled and compared, thereby reducing waste in research.[@R7] The first step in the development of a COS typically involves a review of existing knowledge (eg, systematic review of outcomes used in previous studies) to inform the consensus process.[@R8] In the case of the SCORE-IT study, this has involved a systematic review of outcomes used in registered clinical trials of glucose-lowering interventions for type 2 diabetes.[@R2] While this is typical of many COS, clinical trials often overlook the outcomes that are important to patients[@R9] and so the outcomes identified in such reviews are likely to predominantly reflect the perspectives of researchers and clinicians.[@R11] This is a concern, as there is evidence that the input of patients leads to the identification of core outcomes beyond those identified by practitioners alone.[@R12] Furthermore, the Core Outcome Set-Standards for Development project recently established the inclusion of patient stakeholders within the COS development process to be a minimum standard for COS.[@R16]

Primary qualitative research is particularly suited to accessing patient perspectives on outcomes, as these studies allow patients to voice their views and experiences in an open-ended way and in their own words.[@R17] The findings from such studies can contribute in several ways to COS development including to the 'long list' of outcomes needed in the early stages of the process. However, primary qualitative research can be resource intensive and require study team expertise in qualitative methodology.[@R18] Systematic reviews of qualitative studies potentially provide an alternative to conducting primary qualitative research where suitable published studies are available.[@R17]

Previous systematic reviews of qualitative studies have identified outcomes of importance to patients and informed the development of COS in critical illness, bariatric and metabolic surgery, neonatal care and tuberculosis.[@R19] Such reviews have identified outcomes that were not reported in systematic reviews of clinical trials, indicating that qualitative evidence is needed to ensure that the initial 'long list' of outcomes is comprehensive and does not omit outcomes important to patients.[@R19] However, these previous systematic reviews of qualitative studies have undertaken exhaustive literature searches and are likely to be time consuming and resource intensive.[@R22] Systematic reviews inform the early phases of COS and comprise one small aspect of the COS development process. As many developers have limited time and resources, there is a need to identify an expedited approach for identifying outcomes that are important to patients, which can subsequently inform the development of COS. Existing qualitative reviews for a specific condition could be considered; however, in the case of type 2 diabetes, these reviews[@R23] have not been conducted in the context of COS development and as such group findings into overarching concepts, many of which have little relevance to COS. Here we report an expedited approach for identifying outcomes reported by people with type 2 diabetes when asked about their lived experience.

Aims {#s2}
====

Our aims in undertaking this review were: to identify an expedited approach for incorporating the patient perspective within the initial stages of COS development; to identify outcomes important to people with type 2 diabetes for inclusion in a 'long list' of outcomes for the COS consensus process; and to compare outcomes identified from the qualitative literature with those identified via a previous systematic review of outcomes measured in type 2 diabetes clinical trials. We also aimed to compare outcomes identified from qualitative studies of patients living in low/middle-income countries (LMIC) with outcomes identified from qualitative studies conducted in higher income countries (HIC). The prevalence of diabetes in LMICs is high[@R25] and it is important to examine if outcomes voiced by patients living in LMICs differ from those of patients in HICs.

Methods {#s3}
=======

Search strategy {#s3-1}
---------------

Using rapid review methodology, which involves streamlining traditional systematic review methods to synthesize evidence within a shortened time frame,[@R26] we searched a single health-related database, MEDLINE, with no date restrictions on 22 June 2017. The search terms, which are indicated in [table 1](#T1){ref-type="table"}, comprised qualitative methodological filters previously shown to identify qualitative research from the MEDLINE electronic database.[@R27] The research field for type 2 diabetes is vast and so search filters designed for maximum specificity[@R27] were selected to minimize irrelevant references.

###### 

MEDLINE search strategy

  Multifield search                                                                                                                                                    
  ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ----------
                      (type 2 diabetes OR type II diabetes)                                                                                                            Abstract
  AND                 patient\*                                                                                                                                        Abstract
  AND                 (Qualitative OR Themes)                                                                                                                          Abstract
  AND                 (symptom OR treatment OR living with)                                                                                                            Abstract
  NOT                 (co-morbid\* OR foot ulcers OR retinopathy OR nephropathy OR bariatric surgery OR non-alcoholic fatty liver disease OR cardiovascular disease)   Abstract

Studies reporting qualitative empirical findings of the views and experiences of people with type 2 diabetes on their condition and treatment were eligible for inclusion. Type 1 diabetes, gestational diabetes, type 2 diabetes in children and maturity onset diabetes of the young were outside the scope of this review. Studies where the primary focus was the treatment of diabetes comorbidities or complications (eg, diabetic foot ulcer, diabetic retinopathy, nephropathy, bariatric surgery, non-alcoholic fatty liver disease and cardiovascular disease) were also excluded.

Study selection {#s3-2}
---------------

SLG and NLH identified and screened titles and abstracts from the MEDLINE search for eligibility, batch checked 10% of these to ensure consistency and discussed uncertainties. There was good agreement between reviewers during the batch check; therefore, the two reviewers each reviewed half the remaining abstracts. Full texts were retrieved and reviewed for articles meeting the following inclusion criteria: participants were people with type 2 diabetes or their partners, the focus was type 2 diabetes and not an associated comorbidity, and qualitative data collection methods (interviews or focus groups) were used. SLG and NLH each reviewed half the full-text papers for eligibility.

Data extraction {#s3-3}
---------------

For each included study the following data were extracted:

1.  Study aim.

2.  Participants (number in study, age, sex, number of years with diabetes).

3.  Geographical location of participants.

4.  Qualitative data collection methods used.

5.  Text excerpts relevant to outcomes.

Our approach to identifying text relevant to outcomes was deductive. It is important to note that none of the qualitative studies explicitly aimed to identify outcomes, although they did contain text that we could interpret as relevant to type 2 diabetes outcomes. Such text comprised any reports about how patients felt or functioned in relation to their diabetes and the healthcare or treatment they had received. Others have previously defined such reports as relevant to outcomes if they describe something that could be used to assess the effect of a healthcare intervention on the patient's life.[@R28] We were also guided by this definition. For example, we interpreted the patient quotation, '*I just think I like to get my blood glucose inside the right range, as we should'* as about the outcome 'glycaemic control'. All such text, including participants' quotations about their views and experiences and the authors' commentary, was extracted verbatim from both the results and discussion sections of included papers. This text was entered as a separate row in a Microsoft excel spreadsheet (available on request).

SLG and NLH both reviewed and interpreted outcomes from five included studies and checked these for agreement. They each independently reviewed half of the remaining studies.

Quality appraisal {#s3-4}
-----------------

The role of quality appraisal of qualitative studies in systematic reviews, and whether quality assessment should be used to exclude studies, is debated.[@R30] One reviewer (SLG) quality appraised included studies using Critical Appraisal Skills Programme checklist[@R31] to facilitate our understanding of them rather than to exclude any studies.

Data categorization {#s3-5}
-------------------

For the current review, we drew on content analysis to synthesize data from eligible studies. This approach permitted tabulation and frequency counts[@R32] and thereby facilitated comparison with the outcomes reported in the previous systematic review of type 2 diabetes clinical trials. We used the Core Outcome Measures in Effectiveness Trials (COMET) taxonomy to categorize text from the studies.

Two reviewers (SLG and NLH) discussed each text excerpt relevant to outcomes to agree how to categorize them, referring back to the original article when necessary to resolve ambiguities. The COMET taxonomy is an outcome classification system suitable for classifying outcomes across all trials, COS, systematic reviews and trial registries[@R33] regardless of the condition being investigated. It has been designed to provide high-level differentiation between outcome domains to facilitate uniformity of outcome classification in electronic databases.[@R33] Additionally, COS developers have used the taxonomy to assist the classification of outcomes prior to the consensus stage.[@R34] The taxonomy comprises 38 core domains structured within five top level core areas: death, physiological/clinical, life impact, resource use, and adverse events.

Reviewers categorized text excerpts, considering all 38 core domains of the taxonomy as they did so. Agreement between reviewers (SLG and NLH) was assessed with three batch checks of 10% of all outcomes until 100% agreement was reached. Where uncertainty about an outcome could not be resolved reviewers sought clinical input (JPHW). Where one outcome included multiple components, for example, 'fear of death', which encompasses two discrete outcomes 'fear' and 'death', the outcome was classified under two domains (eg, 'emotional functioning/well-being' and 'mortality/survival') as recommended.[@R33] Outcome categorization was verified by the developer of the COMET taxonomy (SD), who was provided with a list of the outcomes extracted from the included studies, which she categorized blind, without seeing the categorization by the two reviewers. Her outcome categorization was compared with that of the two reviewers and any discrepancies were discussed and resolved.

Results {#s4}
=======

Study characteristics {#s4-1}
---------------------

The search returned 146 articles. Of these, 36 were retained after screening titles and abstracts. Following full-text review a further 10 studies were excluded as they did not meet the inclusion criteria. The flow of studies is shown in [figure 1](#F1){ref-type="fig"}.

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.](bmjdrc-2018-000615f01){#F1}

These 26 included studies involved either qualitative interviews (69%) or focus groups (31%) with a total of 976 patients (median 23 participants, range 5--246) from five continents. All studies included participants with type 2 diabetes with some studies focusing on particular minority groups.[@R37] Time since diagnosis of diabetes ranged from less than 1 year up to 51 years, although this was not reported in all studies. For one study that also included partners of patients,[@R38] content relating to both patients and their partners was included in the synthesis. Another study included both patients and healthcare professionals; however, only data originating from patients were synthesized.[@R43] A summary of included studies is provided in [table 2](#T2){ref-type="table"}.

###### 

Characteristics of included studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID   Aim                                                                                                                                                      Year of publication   Location of study   Participants (n)                               Participant age                      Participant sex                                                                                           Time with diabetes                                                 Data collection method   Outcomes identified (n)
  ---------- -------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------- ------------------- ---------------------------------------------- ------------------------------------ --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------ -------------------------
  [@R42]     Explore behavioral factors affecting what patients do for self-care and why they do it.                                                                  1998                  USA                 51                                             29--69 years (mean=52.9)             Male: 26 (51%), female: 25 (49%)                                                                          0.5--1 year: 4 (8%),\                                              Interviews               24
                                                                                                                                                                                                                                                                                                                                                                                                              1--5 years: 20 (39%),\                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                              \>6 years: 27 (53%)                                                                         

  [@R44]     Investigate the distress associated with type 2 diabetes.                                                                                                2002                  UK                  51                                             Not reported                         Male: 19 (37%), female: 32 (63%)                                                                          Not reported                                                       Focus groups             16

  [@R60]     Explore the views and health beliefs of patients who had experienced a new structured diabetes shared care service.                                      2003                  Ireland             25                                             30--50 years: 6 (24%);\              Male: 15 (60%), female: 10 (40%)                                                                          Not reported                                                       Focus groups             10
                                                                                                                                                                                                                                                               51--70 years: 13 (52%);\                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                               \>70 years: 6 (24%)                                                                                                                                                                                                                        

  [@R58]     Describe personal understandings of illness among patients.                                                                                              2004                  Sweden              44                                             47--80 years (mean=64)               Male: 23 (52%), female: 21 (48%)                                                                          Not reported                                                       Interviews               5

  [@R39]     Explore the relevance of a reframed model of healthcare consultation.                                                                                    2004                  UK                  21                                             Not reported                         Not reported                                                                                              Not reported                                                       Interviews               21

  [@R45]     Investigate patients' perceptions about their illness and treatment strategies to facilitate patient-centered, culture-sensitive clinical skills.        2005                  Taiwan              22                                             44--80 years (mean=60.2)             Male: 12 (55%), female: 10 (45%)                                                                          2--25 years (mean=8.3)                                             Interviews               12

  [@R46]     Explore the self-reported healthcare goals, factors inﬂuencing these goals, and self-care practices of older patients.                                   2005                  USA                 28                                             65--88 years (mean=74)               Male: 12 (43%), female: 16 (57%)                                                                          0--5 years: 11 (39%),\                                             Interviews               15
                                                                                                                                                                                                                                                                                                                                                                                                              \>5 to 10 years: 6 (21%),\                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                              \>10 years: 11 (39%)                                                                        

  [@R47]     Explore medication experiences of patients.                                                                                                              2006                  USA                 138                                            \>70 years: 30 (22%),\               Male: 44 (32%), female: 94 (68%)                                                                          Mean=13 years                                                      Focus groups             31
                                                                                                                                                                                                                                                               \>50 years: 102 (74%)                                                                                                                                                                                                                      

  [@R48]     Identify the obstacles to adherence for patients.                                                                                                        2007                  Europe              246                                            40--80 years (mean=63.8)             Male: 122 (49.6%), female: 124 (49.4%)                                                                    1--22 years (mean=10.2)                                            Focus groups             16

  [@R61]     Describe the experience of benefit and risk assessment for patients when making treatment decisions.                                                     2007                  Canada              18                                             Mean=60 years                        Male: 8 (44%), female: 10 (55%)                                                                           Mean=10.7 years                                                    Interviews               29

  [@R49]     Explore the lived experience of patients converting to insulin therapy.                                                                                  2007                  UK                  8                                              49--72 years                         Male: 4 (50%), female: 4 (50%)                                                                            Not reported                                                       Interviews               25

  [@R50]     Understand and document the perspectives of patients regarding the processes and strategies used to self-manage their chronic condition.                 2008                  Taiwan              41                                             42--81 years                         Male: 22 (54%), female: 19 (46%)                                                                          Mean=9.19 years                                                    Focus groups             27

  [@R38]     Describe cultural and family challenges to illness management in foreign-born Chinese-American patients and their spouses.                               2009                  USA                 40\                                            Mean=62 years                        Male: 16 (40%), female: 24 (60%)                                                                          Mean=8.4 years                                                     Interviews               12
                                                                                                                                                                                                                (20 patients, 20 partners)                                                                                                                                                                                                                                                                

  [@R51]     Explore how women manage their diabetes.                                                                                                                 2009                  USA                 5                                              50--85 years (mean=70.4)             Female: 5 (100%)                                                                                          1--18 years (mean=8)                                               Interviews               16

  [@R62]     Explore how living with diabetes in everyday life was experienced following a self-management intervention program based on motivational interviewing.   2011                  Denmark             22                                             30--72 years                         Male: 10 (45%), female: 12 (55%)                                                                          1--11 years                                                        Focus groups             10

  [@R43]     Explore physicians' and patients' views of patients' difficulty achieving treatment goals.                                                               2012                  USA                 34 patients, 19 physicians\*                   43--70 years (mean=59.8)             Male: 20 (59%), female: 14 (41%)                                                                          3--51 years (mean=12)                                              Interviews               10

  [@R41]     Assess self-management skills of Chinese-Americans.                                                                                                      2012                  USA                 24 (7 poorly controlled, 17 well controlled)   Poorly controlled: mean=56 years,\   Poorly controlled---male: 3 (43%), female: 4 (57%); well controlled---male: 13 (76%), female: 2 (12%),\   Poorly controlled: mean=6.4 years; well controlled: mean=6 years   Focus groups             11
                                                                                                                                                                                                                                                               well controlled: mean=60.6 years     NA: 2 (12%)                                                                                                                                                                                           

  [@R52]     Describe the experiences and ways of coping of older Singaporean Chinese women.                                                                          2013                  Singapore           10                                             60--69 years                         Female: 10 (100%)                                                                                         Not reported                                                       Interviews               26

  [@R53]     Explore the concept of patient values in the context of making decisions about insulin initiation.                                                       2013                  Malaysia            21                                             28--67 years                         Male: 12 (57%), female: 9 (43%)                                                                           Not reported                                                       Interviews               19

  [@R37]     Gain a deeper understanding of the difficulties Vietnamese patients experience when accessing services and managing their diabetes.                      2013                  Australia           15                                             60 to \>70 years: 15 (100%),\        Male: 4 (27%), female: 11 (73%)                                                                           \>1 year: 6,\                                                      Focus groups             24
                                                                                                                                                                                                                                                               \>70 years: 11 (73%)                                                                                                                           \>5 years: 9                                                                                

  [@R54]     Better understand barriers to glycemic control from the patient's perspective.                                                                           2013                  New Zealand         15                                             33--90 years (mean=63.3)             Male: 5 (33%), female: 10 (67%)                                                                           2--30 years (mean=44.3)                                            Interviews               10

  [@R55]     Explore the barriers to diabetes control of middle-aged women.                                                                                           2013                  Syria               12                                             40--65 years                         Female: 12 (100%)                                                                                         4--23 years                                                        Interviews               21

  [@R40]     Identify issues in self-management, and opportunities for community pharmacies to offer self-management support to these populations.                    2013                  Australia           24                                             54--95 years (mean=73)               Male: 10 (42%),\                                                                                          \<5 years: 2,\                                                     Interviews               14
                                                                                                                                                                                                                                                                                                    female: 14 (58%)                                                                                          6--10 years: 8, \>10 years: 14                                                              

  [@R56]     Explore patients' reactions to the diagnosis and their health-related quality of life.                                                                   2014                  Malaysia            12                                             50--62 years                         Male: 5 (42%),\                                                                                           2.5--21 years                                                      Interviews               32
                                                                                                                                                                                                                                                                                                    female: 7 (58%)                                                                                                                                                                                       

  [@R57]     Explore the illness perceptions of patients attending treatment and better understand how they manage their illness.                                     2016                  Ethiopia            39                                             \>70 years: 30                       Male: 20 (51%),\                                                                                          1--25 years                                                        Interviews               31
                                                                                                                                                                                                                                                                                                    female: 19 (49%)                                                                                                                                                                                      

  [@R59]     Investigate patients' perceptions and experiences, self-care and engagement with GP-led integrated diabetes care.                                        2016                  Australia           30                                             \<50 to \>65 years (mean=60.2)       Male: 16 (53%),\                                                                                          Mean=12 years                                                      Interviews               6
                                                                                                                                                                                                                                                                                                    female: 14 (47%)                                                                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Data not included in synthesis.

GP, general practitioner; NA, not applicable.

Quality appraisal {#s4-2}
-----------------

The majority of included studies justified the research design (85%), explained details about the recruitment strategy (81%), took ethical issues into consideration (89%), provided an in-depth description of the data collection (89%) and analysis processes (69%), provided a clear statement of findings (96%), and discussed the implications of the research (81%). In contrast, only a minority of studies adequately described the relationship between the researcher and participants (39%).

Data categorization {#s4-3}
-------------------

A total of 458 individual outcomes were interpreted from the included studies (median 16 outcomes per study, range 5--32) and categorized according to the COMET taxonomy. Thirty-nine outcomes related to multiple domains and were classified under two or more domains. Thus, 501 outcomes were categorized within the 38 taxonomy domains. [Table 3](#T3){ref-type="table"} lists the number of outcomes included in each of the taxonomy domains and the number of studies that included outcomes belonging to each domain.

###### 

Outcome categorization according to the COMET taxonomy

  Core area                                                                                        Core domains                          Studies including one or more outcomes in core domain, n (%)   Outcomes included in core domain, n (%)
  ------------------------------------------------------------------------------------------------ ------------------------------------- -------------------------------------------------------------- -----------------------------------------
  Death                                                                                            Mortality/survival                    10 (39)                                                        10 (2)
  Physiological/clinical                                                                           Blood and lymphatic system outcomes   0                                                              0
  Cardiac outcomes                                                                                 5 (19)                                5 (1)                                                          
  Congenital, familial and genetic outcomes                                                        0                                     0                                                              
  Endocrine outcomes                                                                               1 (4)                                 1 (\<1)                                                        
  Ear and labyrinth outcomes                                                                       0                                     0                                                              
  Eye outcomes                                                                                     8 (31)                                9 (2)                                                          
  Gastrointestinal outcomes                                                                        1 (4)                                 2 (\<1)                                                        
  General outcomes\*                                                                               19 (73)                               42 (8)                                                         
  Hepatobiliary outcomes                                                                           1 (4)                                 1 (\<1)                                                        
  Immune system outcomes                                                                           0                                     0                                                              
  Infection and infestation outcomes                                                               3 (12)                                3 (1)                                                          
  Injury and poisoning outcomes                                                                    1 (4)                                 1 (\<1)                                                        
  Metabolism and nutrition outcomes                                                                26 (100)                              63 (13)                                                        
  Musculoskeletal and connective tissue outcomes                                                   1 (4)                                 1 (\<1)                                                        
  Outcomes relating to neoplasms: benign, malignant and unspecified (including cysts and polyps)   0                                     0                                                              
  Nervous system outcomes                                                                          4 (15)                                4 (1)                                                          
  Pregnancy, puerperium and perinatal outcomes                                                     0                                     0                                                              
  Renal and urinary outcomes                                                                       11 (42)                               13 (3)                                                         
  Reproductive system and breast outcomes                                                          0                                     0                                                              
  Psychiatric outcomes                                                                             5 (19)                                7 (1)                                                          
  Respiratory, thoracic and mediastinal outcomes                                                   1 (4)                                 1 (\<1)                                                        
  Skin and subcutaneous tissue outcomes                                                            0                                     0                                                              
  Vascular outcomes                                                                                10 (39)                               12 (2)                                                         
  Life impact                                                                                      Social functioning                    14 (54)                                                        28 (6)
  Role functioning                                                                                 16 (62)                               20 (4)                                                         
  Physical functioning                                                                             24 (92)                               72 (14)                                                        
  Emotional functioning/well-being                                                                 24 (92)                               106 (21)                                                       
  Cognitive functioning                                                                            12 (46)                               15 (3)                                                         
  Global quality of life                                                                           3 (12)                                3 (1)                                                          
  Perceived health status                                                                          5 (19)                                5 (1)                                                          
  Delivery of care                                                                                 18 (69)                               43 (9)                                                         
  Personal circumstance                                                                            7 (27)                                12 (2)                                                         
  Resource use                                                                                     Economic                              0                                                              0
  Hospital                                                                                         0                                     0                                                              
  Need for intervention                                                                            9 (35)                                10 (2)                                                         
  Societal/carer burden                                                                            2 (8)                                 2 (\<1)                                                        
  Adverse events                                                                                   Adverse events/effects                8 (31)                                                         10 (2)

\*The COMET taxonomy defines 'general outcomes' to include those affecting the whole body, which cannot be attributed to a certain body system, for example, fatigue, malaise, pain (unspecified, not associated with a particular body system), fever (not attributable to infection), anthropometric measures (eg, weight), 'global' measures, 'symptoms' (not associated with a particular body system), 'physical health' and fitness.[@R45]

COMET, Core Outcome Measures in Effectiveness Trials.

Of the 501 outcomes, 10 (2%) concerned death, 165 (33%) were physiological/clinical, 304 (61%) were associated with life impact, 12 (2%) related to resource use and 10 (2%) pertained to the adverse events core area. Most outcomes fell within the core domains of 'emotional functioning/well-being', 'physical functioning' and 'metabolism and nutrition'. Outcomes relating to each of these three domains were identified in more than 90% of included studies and, when combined, comprised 48% of the total outcomes.

Emotional functioning/well-being {#s4-4}
--------------------------------

Over one-fifth of the derived outcomes related to 'emotional functioning/well-being' (n=106). These outcomes were identified in 24 of the 26 included studies (92%). In 16 studies, patients described being fearful,[@R41] with fears relating to medication side effects, treatment escalation, needing insulin injections, dying, uncertainty about the future, and developing complications, such as foot damage, paralysis and loss of eyesight. Relatedly, 10 studies[@R39] described patients feeling worried or anxious about symptoms, complications, health deterioration, and ultimately dying prematurely as a result of their diabetes. Patients also commented on how diabetes was a burden[@R44] and reported experiencing aggression and frustration,[@R38] sadness and depression,[@R37] guilt[@R43] and hopelessness.[@R43]

Physical functioning {#s4-5}
--------------------

A total of 72 (14%) outcomes concerning physical functioning were derived from 24 included studies (92%). Exercise was identified as an outcome in 16 studies, with patients acknowledging the importance of regular exercise and the benefits it brings; however, some patients labelled it a burdensome activity, which they had difficulty engaging in.[@R37] In 15 studies, patients referred to the self-monitoring activities they engaged in to manage their diabetes, for example, regularly checking blood glucose levels,[@R37] with many emphasizing that the need for a strict self-management regime had become a burden on their lives. Dietary restrictions were a common difficulty relating to self-management, with many patients articulating a desire for dietary freedom, where they could eat what they want, when they want.[@R37]

Metabolism and nutrition {#s4-6}
------------------------

Outcomes relating to metabolism and nutrition were identified in all of the 26 included studies, with 63 (13%) outcomes identified in total. In 20 studies, patients made references to their diet, explaining how healthy eating was necessary for controlling their blood sugar levels.[@R37] In 17 studies, patients spoke about blood glucose-level fluctuations, the importance of glycemic control and the consequences of blood glucose levels falling outside the appropriate range.[@R38] Relatedly, 12 studies referred to hypoglycemia, including patients' concerns over what would happen if they did experience a hypoglycemic episode, fears about the physical symptoms and the steps they would take to avoid hypoglycemia.[@R37]

Outcomes identified from studies conducted in LMICs {#s4-7}
---------------------------------------------------

Of the 26 included studies, four (15%) were conducted in LMICs.[@R63] These four LMIC studies included one upper middle-income country (Malaysia),[@R53] one lower middle-income country (Syria)[@R55] and one least developed country (Ethiopia).[@R57] The most prevalent outcome domains among the LMIC studies were 'mortality/survival', 'general outcomes', 'metabolism and nutrition', 'role functioning', 'physical functioning', 'emotional functioning/well-being' and 'delivery of care'. Outcomes relating to these seven domains were derived from 100% of the LMIC studies. Five of these seven domains were also among the most reported in the studies conducted in HICs; however, outcomes associated with the 'mortality/survival' and 'role functioning' domains were less frequently reported in HIC studies, at 27% and 55% of studies, respectively. Additionally, outcomes relating to two of the domains, 'endocrine outcomes' (eg, pancreatic function) and 'hepatobiliary outcomes' (eg, liver complications), were only derived from the LMIC studies.

Comparison with outcomes identified in systematic review of clinical trials {#s4-8}
---------------------------------------------------------------------------

We compared the outcomes derived from the qualitative studies with the outcomes identified from the recent systematic review of type 2 diabetes registered clinical trials.[@R2] [Table 4](#T4){ref-type="table"} shows the number of outcomes identified from both reviews according to the five core areas of the COMET taxonomy. In total, 1446 outcomes were identified from the clinical trials review and 458 outcomes from the review of qualitative studies. Both reviews identified a similar proportion of outcomes related to death, resource use and adverse events. However, the systematic review of clinical trials identified a higher proportion of physiological/clinical outcomes (84% vs 33%), whereas the qualitative studies identified a greater proportion of life impact (61% vs 10%) outcomes. Several domains were only identified in one or other of the reviews. Outcomes relating to the 'blood and lymphatic system', 'immune system', 'skin and subcutaneous tissue', 'economic resource use' and 'hospital resource use' were only extracted from the clinical trials, whereas outcomes associated with 'injury and poisoning' (eg, injuries associated with insulin injections), 'personal circumstances' (eg, patients' support networks) and 'societal/carer burden' (eg, patients wanting to be independent and not wanting to be a burden to their family) were only identified in the qualitative studies.

###### 

Number of outcomes identified in the systematic review of clinical trials and synthesis of qualitative literature according to the five core areas within the COMET taxonomy

                           Outcomes identified in systematic review of clinical trials, n (%)   Outcomes identified in synthesis of qualitative literature, n (%)
  ------------------------ -------------------------------------------------------------------- -------------------------------------------------------------------
  Death                    3 (\<1)                                                              10 (2)
  Physiological/clinical   1221 (84)                                                            165 (33)
  Life impact              145 (10)                                                             304 (61)
  Resource use             31 (2)                                                               12 (2)
  Adverse events           46 (3)                                                               10 (2)

COMET, Core Outcome Measures in Effectiveness Trials.

Discussion {#s5}
==========

This review has identified an expedited approach for incorporating patient perspectives within the early stages of COS development. In contrast to previous similar reviews, which have involved exhaustive searches,[@R19] the streamlined nature of the current review enabled rapid identification of patient-centered outcomes that can be used to contribute to the development of the 'long list' of outcomes to inform the COS consensus process.

To our knowledge, this is the first review of qualitative studies to identify outcomes that are important to people with type 2 diabetes. The findings will be used, alongside a review of outcomes measured in clinical trials,[@R2] in the development of a COS for type 2 diabetes. Importantly, this review of qualitative studies has identified outcomes that have not previously been measured in type 2 diabetes clinical trials. Without this review, these outcomes would not have been identified for inclusion in the 'long list' of outcomes to go forward to the Delphi study.

Most outcomes identified from the qualitative studies related to life impact, whereas in the review of registered clinical trials a relatively small proportion of outcomes related to life impact.[@R2] If clinical trial reviews are used as the only source for developing 'long list' of outcomes for COS consensus processes, life impact outcomes may become sidelined in favor of outcomes more frequently measured in clinical trials. This is reflected in the COMET database, where far fewer COS encompass life impact outcomes, in contrast to many COS that encompass physiological/clinical outcomes.[@R33] Thus, the current review supports the recommendation by Dodd and colleagues[@R33] for COS developers to give greater attention to outcomes of life impact. It also illustrates how conducting reviews of qualitative studies can help, alongside other steps such as including patients as participants in COS studies and involving patients and the public in the design of such studies, to ensure COS reflect outcomes that matter to patients.

Given uncertainties about how far COS are applicable beyond those countries that the participants in the development process have been drawn from, it is striking that 84% of published COS studies have not included any participants from LMICs.[@R64] While few qualitative studies had been conducted in LMICs, our review has enabled us to compare outcomes identified in LMIC and HIC studies. Outcomes relating to 'mortality/survival' were identified in all LMIC studies, yet almost three-quarters of HIC studies made no references to these outcomes. This is most likely due to the higher prevalence of diabetes-related deaths in LMICs.[@R25] Similarly, all LMIC studies reported outcomes relating to 'role functioning' (eg, ability to work and managing family responsibilities) while almost half of the HIC studies made no references to these outcomes. Being unable to function in one's life roles is likely to be more detrimental to patients living in LMICs.[@R65] Furthermore, three domains relating to diabetes-related complications were only reported in the LMIC studies. Complications are expensive to treat in LMICs, which represent less than 20% of the world's diabetes care-related expenditure.[@R66] It is possible that national economic factors influence which outcomes are important to patients, indicating the importance of ensuring that the perspectives of patients in LMICs are incorporated into COS development processes.

Strengths and limitations {#s5-1}
-------------------------

This study has identified an expedited approach for incorporating the patient perspective into the initial stages of COS development. Our review has enabled evidence from a large number of patients living in a diversity of countries to contribute to the early stages of COS development. We anticipate that such reviews could be performed by COS developers without specialist expertise in qualitative methods, although relevant training would be helpful. Additionally, the method is less resource intensive than other methods for reviewing qualitative evidence which makes it feasible as part of a wider COS process. However, there are some methodological limitations. In line with our expedited approach and recommendations from previous studies,[@R67] we only searched one database (MEDLINE) and did not search gray literature. While this approach may mean that some relevant studies may have been missed, our aim was not to provide a comprehensive overview of all research relating to patients' views and perceptions of type 2 diabetes. Rather, to provide an expedited approach for identifying outcomes that are important to patients, as part of a wider process to incorporate the patient perspective in COS development. In comparison to other qualitative systematic reviews we identified few articles for screening, which reflects the specificity[@R27] of our search terms. Despite these limitations, the number of studies included in this rapid review is comparable to other reviews of qualitative evidence.[@R19]

A further limitation is that our inclusion of studies relating to a specific experience (eg, patients' reactions to their diagnosis)[@R56] or intervention (eg, the views of patients who had experienced a new structured diabetes shared care service)[@R60] may have impacted on the outcomes identified. However, when extracting data from such studies we focused on patients' general views and experiences of diabetes; we did not extract data that focused solely on patients' perspectives of specific experiences or interventions. An additional limitation is that while many studies in our review were inductive, our approach to reviewing them and deriving outcomes was deductive. Specifically, categorizing text excerpts according to the COMET taxonomy may have transformed their meaning or diluted the patient perspective. However, this categorization enabled us to compare the different literatures in a common 'currency', which was key to identifying differences in the types of outcomes given prominence in the clinical trials versus the qualitative literatures, and differences in the qualitative studies from LMICs and HICs. Finally, our review was largely aggregative, collecting findings of previous studies and describing these according to a predefined taxonomy to allow comparison and address specific aims, rather than a configurative review which seeks to interpret the experiences of patients or generate new theory about these.[@R69] Nevertheless, we hope the pragmatic and resource-efficient nature of our method helps the field of COS development by making it easier to incorporate patients' perspectives.

Conclusion {#s6}
==========

This rapid review of qualitative studies identified outcomes that are important to people with type 2 diabetes and its findings will inform the development of a COS for clinical trials of glucose-lowering interventions in people with type 2 diabetes. These patient-derived outcomes contrasted with those identified from a systematic review of clinical trials, pointing to the importance of incorporating patient perspectives from the outset of COS development. Additionally, this review also emphasized the importance of ensuring that patients in LMICs are able to input into the development of COS.
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